AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

PURPOSE: Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (aBC). PATIENTS AND METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Tolaney, Sara M., Chan, Arlene, Petrakova, Katarina, Delaloge, Suzette, Campone, Mario, Iwata, Hiroji, Peddi, Parvin F., Kaufman, Peter A., De Kermadec, Elisabeth, Liu, Qianying, Cohen, Patrick, Paux, Gautier, Wang, Lei, Ternès, Nils, Boitier, Eric, Im, Seock-Ah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461947/
https://www.ncbi.nlm.nih.gov/pubmed/37348019
http://dx.doi.org/10.1200/JCO.22.02746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461947/
https://www.ncbi.nlm.nih.gov/pubmed/37348019
http://dx.doi.org/10.1200/JCO.22.02746

Ejemplares similares